Market accessOfficial
AIFA activates web monitoring registry for ZIIHERA in HER2-positive biliary tract cancer
🇮🇹 AIFA · Thu 19 Nov 2026
From 19 November 2026, Italian centres can use zanidatamab through AIFA's monitoring registry for the one indication admitted to reimbursement.
The Italian Medicines Agency (AIFA) has announced that, from 19 November 2026, ZIIHERA (zanidatamab) can be used through a monitoring registry for the indication admitted to reimbursement. The notice cites Determina Pres/1590, which entered into force following a notice in the Gazzetta Ufficiale no. 269 of 18 November 2026.
Subscribe to keep reading
$4.99 / month
- Every article, analysis and opinion piece on VigiEye and CompePharma
- One subscription for both sites, cancel any time
or
Article written by VigiEye from the official source (AIFA). AI-assisted; check the source before acting.
More Market access
All →
SÚKL publishes draft Czech reimbursement list effective 20 November 2026
🇨🇿 SÚKL · Fri 20 Nov 2026
SÚKL launches expanded ASTERx system for pricing and reimbursement proceedings, retires Verso
🇨🇿 SÚKL · Fri 20 Nov 2026
AIFA publishes outcomes of November Scientific and Economic Committee meeting
🇮🇹 AIFA · Fri 20 Nov 2026
Nova Biomedical starts field safety action on StatStrip ketone test strips over QC failures
🇳🇱 IGJ · Thu 19 Nov 2026
Getinge recalls CARDIOSAVE balloon pumps in Canada over reversed-polarity capacitors
🇨🇦 Health Canada · Thu 19 Nov 2026
ICU Medical recalls Portex endotracheal tubes in Canada over plasticizer variability in resin
🇨🇦 Health Canada · Thu 19 Nov 2026